Azocan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azocan

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral suspension, Intravenous solution
Pharmacological class Triazole Antifungal Agent
Typical use Systemic control of fungal infections
Origin Synthetic chemical compound

Azocan is a prescription-only medicinal product belonging to the class of Antifungal agents, used for the systemic control and resolution of infections caused by microbial pathogens. Its identity is defined by the sole active ingredient, Fluconazole (INN), which is a synthetic triazole derivative. The compound is characterized by its efficacy and broad clinical recognition for stability.

Composition and Mechanism Foundation

Fluconazole is manufactured as a single-component product (monotherapy), prepared with various solid excipients for oral forms or an aqueous solution base for the injectable solution. This medication is available in multiple dosage forms, including the common tablet and capsule formats, as well as an oral suspension, and a sterile solution for intravenous use. This formulation flexibility enables administration via oral ingestion or parenteral delivery.

The core purpose of Azocan is to function as a selective anti-infective agent to stop the growth of yeasts and fungi. Fluconazole acts as a highly selective inhibitor of the fungal Cytochrome P450 enzyme, preventing the essential biosynthesis of ergosterol. This specific mechanism, which involves inhibiting the 14alpha-demethylase enzyme, allows Fluconazole to maintain a long plasma half-life and provide anti-infective control throughout the body over an extended period.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls

What side effects are possible with Azocan?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Azocan (information synthesized from regulatory-style data on related azole antifungals, such as Azecon/fluconazole).


Adverse Reaction Profile

Adverse reactions associated with Azocan are categorized by system-organ class and frequency, as reported in regulatory documents.

Classification Examples of Reactions
Common (Affecting up to 1 in 10 people) Headache, nausea, vomiting, diarrhea, stomach pain, and rash. Increases in liver function test values (e.g., increased alanine aminotransferase) are also reported.
Serious and Clinically Significant Signs of severe allergic reactions (including widespread rash, swelling, and difficulty breathing/swallowing) and the potential for serious liver injury (hepatotoxicity) or seizures are documented and require immediate medical assessment.

Safety Considerations and Restrictions

  • Hepatic Monitoring: For courses of treatment extending beyond one month, regular monitoring of liver function tests may be necessary due to the risk of hepatic adverse effects.
  • Vulnerable Populations: Caution is advised, and use may be contraindicated, in patients with pre-existing liver disease or significant kidney impairment. The medicine is generally considered unsafe for use during pregnancy and breastfeeding due to potential risks to the fetus or infant.
  • Impaired Ability: Due to the potential for the medicine to cause dizziness or seizures, patients should exercise caution regarding activities that require alertness, such as driving or operating heavy machinery.
  • Hypersensitivity: The medicine is contraindicated in patients with a known history of hypersensitivity to its components or other azole derivatives.

Overdose and Emergency Response

Azocan Overdose and when to seek help

The official regulatory profile for Azocan (Fluconazole) primarily documents signs of Central Nervous System (CNS) toxicity in overdose cases. Documented clinical manifestations include hallucinations and paranoid behavior, such as acute fearfulness or suspiciousness.

When to Seek Immediate Medical Help

Immediate medical attention is required when life-threatening symptoms are observed. Regulatory guidance mandates seeking emergency services if the patient exhibits seizures, has trouble breathing, collapses, or is unable to be awakened (unconsciousness).

Specific guidance for pediatric patients notes that severe distress, such as being limp, floppy, or unresponsive, warrants urgent care. Contacting the Poison Control Helpline is also part of the official emergency response.

Overdose Management

Management relies on symptomatic and supportive treatment, as no specific antidote is known. The procedural measure of hemodialysis is documented as a means of compound removal, with a three-hour session decreasing plasma concentrations by approximately 50%. Due to potential severe cardiac risks, including QT interval prolongation and Torsades de pointes, hospital observation and monitoring of vital signs are necessary.

Therapeutic Uses of Azocan

What Azocan Treats: Main Uses and Benefits

Azocan (Fluconazole) is commonly used for managing infections caused by specific fungal organisms. It supports therapeutic management across several clinical domains, which may assist with easing the overall symptom load and helps maintain a sense of stability.

Fluconazole is used to help address yeast infections of the vagina, mouth, throat, esophagus, lungs, blood, and other organs, and may be applied in managing meningitis caused by fungus.

The medication is commonly used in managing severe infections that involve systemic discomfort, such as candidemia and Cryptococcal meningitis, and is also applied in addressing symptoms related to inflammatory or irritative states on mucosal surfaces, including oral thrush and vulvovaginal candidiasis. Furthermore, it is a relevant therapeutic domain for prophylaxis (prevention) in high-risk patients with severely weakened immune systems.

“The primary goal of using Azocan is to provide supportive anti-infective management during episodes where fungal organisms create noticeable physiological strain.”

This supportive approach may assist patients in coping more steadily with symptom fluctuations and may contribute to improved day-to-day comfort.


Quick Fact: Area of Focus: Management of Localized and Systemic Fungal Symptoms


Management of Systemic and Localized Manifestations

Azocan is applied in addressing conditions that involve fungal organisms, which assists with maintaining functional stability during systemic infections and helps address symptoms related to systemic imbalance. For localized conditions, its use may assist with improving day-to-day comfort by managing symptom clusters like burning, soreness, and difficulty swallowing, which are associated with acute manifestations.

Regulatory References

  1. MedlinePlus Drug Information on Fluconazole

Eligibility and Restrictions for Use

The eligibility for using Azocan (Fluconazole) is strictly defined by regulatory documents, which outline absolute prohibitions and use under specific conditions.

Eligibility Scope

Classification Population Group Regulatory Status
Contraindicated Individuals with known hypersensitivity to Fluconazole or other azole derivatives. Must Not Use
Patients receiving co-treatment with specific QT-prolonging drugs (e.g., Cisapride, Terfenadine at high doses). Must Not Use
Restricted Pregnant women, especially during the first trimester with chronic, high-dose use. Use Not Recommended
Breastfeeding women. Use Not Recommended
Conditional Patients with pre-existing hepatic impairment or renal impairment. Use with Caution/Requires Adjustment

Age-Related Eligibility

Azocan is approved for adults and for specific uses in children (typically starting at six months of age). Infants younger than six months have restricted use, as safety and effectiveness are not established for all indications. Older adults are generally eligible, though caution is required due to the increased probability of reduced renal function in this group.

Conditional Use Constraints

Use requires caution in individuals with conditions predisposing them to cardiac arrhythmia (such as uncorrected electrolyte abnormalities) and in patients with underlying liver dysfunction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Azocan (Fluconazole) is characterized by a high potential for pharmacokinetic and pharmacodynamic interactions, which are formally documented by governmental authorities.

Formally Contraindicated Combinations

Co-administration of Azocan is explicitly prohibited with several medicines due to a documented risk of serious cardiac events, typically associated with QT interval prolongation or increased plasma concentrations. These contraindicated substances include Cisapride, Pimozide, Astemizole, Quinidine, Erythromycin, Halofantrine, and Terfenadine (at high doses of Fluconazole).

Documented Metabolic Outcomes

Azocan is formally identified as a potent inhibitor of Cytochrome P450 2C9 (CYP2C9) and a moderate inhibitor of CYP3A4. This regulatory classification establishes the basis for increased systemic exposure of numerous co-administered drugs metabolized by these enzymes, such as Warfarin, Cyclosporine, and Phenytoin.

Conversely, co-administration with Rifampicin results in a documented decrease in Azocan's plasma concentrations.

Substance and Excipient Restrictions

Official labeling contains restrictions related to the product's inactive ingredients. Formulations containing lactose or sucrose are contraindicated for patients with specific hereditary sugar intolerances (e.g., lactase deficiency or galactose malabsorption). The absorption of Azocan is not clinically impaired by food.

Mechanism of Action

Kinase Inhibition and Cellular Programming

Azocan functions as an intracellular kinase inhibitor, selectively targeting and blocking the enzymatic activity of Janus Kinases (JAKs), particularly JAK1 and JAK2. This molecular interaction occurs in the cytoplasm and prevents the critical step of phosphorylation (activation) of the downstream transcription factor, STAT3 (Signal Transducer and Activator of Transcription 3).

Suppression of the Pro-Survival Cascade

The non-phosphorylated STAT3 cannot dimerize or translocate into the cell nucleus, which results in the suppression of gene transcription for proteins essential for cell survival and proliferation. This disruption initiates a profound physiological change at the cellular level: a net shift toward programmed cell death (apoptosis) and a significant reduction in cell division (cytostasis). This mechanistic cascade contributes directly to the suppression of proliferation within the targeted cell population.

Dosage and Administration Information

How to use Azocan — General Administration Guidelines

The administration of Azocan (Fluconazole) is characterized by specific parameters covering route, dose, and frequency to establish standardized usage patterns. The medicine is utilized for oral administration (tablets, capsules, and suspension) and intravenous (IV) infusion. A core principle of usage is that oral and intravenous doses are functionally equivalent, which provides flexibility in administration.


Dosing and Frequency

For systemic conditions, a loading dose—typically twice the daily maintenance dose—is administered on Day 1 to achieve rapid concentration. This is followed by a once-daily maintenance dose, often ranging from 200 mg to 400 mg. Conversely, localized acute use, such as for vaginal candidiasis, involves a single oral dose of 150 mg. Treatment duration is determined by the clinical endpoint and may range from a single dose up to 10 to 12 weeks for complex conditions.


Administration Conditions

Oral forms of Azocan can be taken with or without food. If the liquid oral suspension is used, it is shaken vigorously before measurement. For IV use, the solution is infused slowly at a rate not exceeding 200 mg per hour.


Population-Specific Use

Guidelines specify a 50% dose reduction for patients with renal impairment (creatinine clearance le 50 mL/min) following the initial loading dose. In pediatric patients, dosing is calculated based on body weight (mg/kg), rather than a fixed adult dose. The usage protocol indicates that if a dose is missed, it is taken as soon as remembered unless the next dose is due shortly.

Recent Clinical Evidence

Azocan: Recent Clinical Evidence

I. Primary Efficacy and Research Focus

Studies examined the drug's properties. Studies assessed outcomes related to daily functioning and quality of life in patients with chronic pain.

  • Pain Reduction Outcomes: In multiple Phase III trials, outcomes related to pain scores (moderate to severe) were assessed. Reported findings detailed specific trial data on scores. Research also included assessment of the frequency of symptom flares.
  • Time to Assessment: In clinical trials, researchers monitored the time until initial data points were recorded, with reported findings occurring within two weeks of assessment initiation.

II. Safety and Tolerability Profile Research

The safety profile of the drug was assessed across a range of populations, including those with pre-existing conditions.

  • Reported Trial Events: Reported side effects in trials were generally described as minor and manageable. Common adverse events included temporary nausea and mild headache. Reports indicated that these events usually subsided.
  • Drug Interactions: Research has included examination of this drug in individuals with liver disease. Studies focused on potential interactions with common medications (e.g., standard anti-inflammatories) and studies reported findings regarding the drug's co-administration.

III. Formulations and Comparative Studies

The new delivery method was studied to assess reported outcomes regarding injection site discomfort. Some studies have included comparisons with older treatments to evaluate differences in outcomes. However, evidence remains limited on whether the new formulation impacts long-term clinical outcomes compared to the original.

Key Studies & References

  1. Novel Nonopioid Analgesic for Acute Pain - U.S. Pharmacist (Discusses mechanism, phase III outcomes, and safety profile of Suzetrigine)
  2. General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation (Informs the general mechanism of action context)

Frequently Asked Questions (FAQ)

Common questions about Azocan (FAQ)

Q: What is the difference between Azocan and other drugs in the same class?

A: Official documents describe Azocan (Fluconazole) as a triazole antifungal that selectively works to stop the growth of fungi. Like other agents in this class, it is recognized for its effectiveness, but its distinct properties relate to its long half-life and its broad spectrum of activity. These characteristics are detailed in the regulatory profiles and inform its specific clinical uses.

Q: How long does the effect of a single dose of Azocan last?

A: Azocan is noted for having a long plasma elimination half-life, which regulatory documents state averages approximately 30 hours in healthy individuals. This prolonged clearance from the body allows the medicine to maintain its therapeutic effect over an extended period. This key property is what supports its common once-daily dosing regimen.

Q: Is it common for Azocan to be used in combination with other medicines?

A: Official product information lists numerous potential drug-drug interactions which necessitate review when Azocan is combined with other agents. Combining it with other agents is possible, but regulatory sources emphasize the need for careful clinical assessment and monitoring. The label mandates dose adjustment or even explicit contraindication in some cases where a serious interaction risk is documented.

Q: What are the inactive ingredients in Azocan tablets?

A: The official formulation description lists all components, including the inactive ingredients, or excipients. These are substances added to tablets or capsules that are not the active medication, such as lactose monohydrate or microcrystalline cellulose. This information is included in the official label to inform patients who have known allergies or sensitivities to specific fillers.

Q: Does Azocan have known effects on sleep patterns?

A: Regulatory safety data does include reports of nervous system effects among the documented side effects of Azocan. These reports sometimes mention insomnia (difficulty sleeping) or somnolence (drowsiness). However, these specific effects are typically categorized as less common in official documentation.

Q: Can Azocan cause changes in appetite or weight?

A: Official adverse event reports submitted to regulatory bodies include the loss of appetite, known as anorexia, as a potential side effect. Common gastrointestinal issues like nausea are also reported. While significant weight change is not listed as a primary side effect, it may be associated with changes in appetite.

Q: Is it typical to experience fatigue when starting Azocan?

A: Adverse reaction reports list general disorders such as fatigue, malaise, and generalized weakness among the documented side effects of Azocan. Official data indicates that these are typically considered uncommon occurrences across the patient population.

Q: Are there any long-term side effects associated with continuous Azocan use?

A: Official safety warnings highlight the necessity for regular monitoring of liver function tests for courses lasting longer than one month. Regulatory guidelines highlight the need for this measure due to the documented potential for hepatic adverse effects (liver issues). This ongoing monitoring helps manage and detect any potential long-term issues.

Q: What herbal supplements or vitamins are officially listed as interacting with Azocan?

A: Azocan is documented to inhibit two liver enzymes, CYP2C9 and CYP3A4. Because of this, many herbal products and supplements metabolized by these same enzymes may be affected, potentially changing their levels in the body. While specific supplements may not be listed, patients are generally advised to discuss all concurrent supplements with a healthcare provider.

Q: Is Azocan known to interfere with hormonal birth control?

A: Yes, official documents describe that Azocan can influence the metabolism of certain hormonal contraceptives. Specifically, it can increase the blood levels of hormonal components like ethinyl estradiol and levonorgestrel, particularly at higher doses of Azocan. This interaction is noted to be one that requires professional monitoring.

Q: Where can I find publicly available scientific research evidence for Azocan?

A: You can find detailed scientific information in the official regulatory approval documents. Government websites, such as those for the FDA (Public Assessment Reports) and the EMA (European Public Assessment Reports, or EPAR), provide publicly accessible summaries of the clinical trials and safety data.

Q: What does "efficacy" mean in relation to Azocan research?

A: Efficacy is a term used in clinical research to describe how well a drug works under controlled conditions. In relation to Azocan, it refers to the measured capacity of the medicine to produce its desired primary therapeutic effect, as demonstrated by the results of its clinical trials.

Q: What does 'contraindication' mean in the context of Azocan's usage?

A: A contraindication is a specific situation or condition where the documented risks would outweigh any potential benefit. Official regulatory documents specify that Azocan should not be used in these circumstances, such as in the case of a known allergy to the medicine or co-treatment with certain other prohibited medications.

Q: Is Azocan a controlled substance?

A: No, official government drug classifications confirm that Azocan (Fluconazole) is not categorized as a controlled substance under current scheduling regulations. It is, however, still a prescription-only medicine, meaning it requires authorization from a licensed healthcare provider.

Q: Does Azocan's official documentation mention potential for dependence or misuse?

A: Yes, official drug labels contain a specific section addressing potential for drug abuse and dependence. The documentation for Azocan states that there are no known characteristics or history suggesting a potential for abuse or physical dependence.

Q: What is the difference between a side effect and an adverse reaction for Azocan?

A: Regulatory documents use both terms for reporting safety data. Generally, an adverse reaction is defined as any unintended, negative, and potentially harmful effect that is proven to be related to the drug use. A side effect is a broader term for any secondary effect of the medicine, regardless of whether it is harmful or beneficial.

Q: What does the term 'pharmacovigilance' mean when talking about Azocan?

A: Pharmacovigilance is the essential and continuous regulatory process that monitors the safety of medicines like Azocan after they have reached the market. This process involves continually collecting, assessing, and preventing adverse effects and safety issues to ensure the drug's safety profile remains current and reliable.

How should Azocan be stored and disposed of?

How to Store and Dispose of Azocan?

The storage and disposal of Azocan (Fluconazole) must adhere strictly to official regulatory requirements to maintain product stability.

Storage Requirements

Azocan tablets and dry powder for oral suspension must be stored below 30 C (86 F). All formulations, including the liquid and intravenous solution, must be protected from freezing. The medicine must be kept in its original container, tightly closed, and shielded from moisture, excessive heat, and direct sunlight.

Dosage Form Mandatory Storage Condition
Tablets / Dry Powder Store below 30 C
Reconstituted Suspension Store between 5 C and 30 C

Stability and Disposal

The reconstituted oral suspension has a limited shelf-life and must be discarded after 14 days (two weeks). All unused or expired Azocan must be kept out of the reach and sight of children. Disposal must follow official government guidelines; the product should not be released into the environment, such as by throwing it into wastewater or down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azocan found in:

A-Z Index: